Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche reports Q3 earnings - looks to Tecentriq for future

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Oct 31, 2022 12:30pm

151 Views

Post# 35060405

RE:RE:RE:Roche reports Q3 earnings - looks to Tecentriq for future

Do not know who sold them to me, but I bought 800 shares through TD. Yes this morning.

As you know I was undecided, and decided to add. One of your posts on sequencing was influential in my thinking

I said Bonne Chance because I am under no illusions that that a share price increase is guaranteed.

This is a biotech and given the past performance, one needs to be careful.

Any further nonsense from you, and I say piff off.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario